Long-term, naturalistic treatment with olanzapine, risperidone, quetiapine, or haloperidol monotherapy: 24-month results from the intercontinental schizophrenia outpatient health outcomes (IC-SOHO) study
Objective. To compare the effectiveness of olanzapine, risperidone, quetiapine, or haloperidol monotherapy in patients with schizophrenia who were treated in routine clinical practice settings for a period of 2 years. The incidence and persistence of adverse events encountered during long-term thera...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Published: |
2008
|
| Subjects: |
| _version_ | 1796946170081181696 |
|---|---|
| author | Lee, P. Kim, C.E. Kim, C.Y. Lin, W. W. Habil, H. Dyachkova, Y. McBride, M. Dossenbach, M. |
| author_facet | Lee, P. Kim, C.E. Kim, C.Y. Lin, W. W. Habil, H. Dyachkova, Y. McBride, M. Dossenbach, M. |
| author_sort | Lee, P. |
| collection | UM |
| description | Objective. To compare the effectiveness of olanzapine, risperidone, quetiapine, or haloperidol monotherapy in patients with schizophrenia who were treated in routine clinical practice settings for a period of 2 years. The incidence and persistence of adverse events encountered during long-term therapy are also reported. Method. Outpatients with schizophrenia who entered this 3-year, prospective, observational study were classified according to their initially prescribed antipsychotic monotherapy: olanzapine (n=3222), risperidone (n=1116), quetiapine (n=189), or haloperidol (n=256). Patients were included in the analysis for as long as this treatment was maintained. Results. Over 2 years, olanzapine recipients had significantly (P0.001) greater reduction in overall CGI-S score (and the negative, depressive, and cognitive symptoms domains), lower incidence of sexual and motor dysfunction, and greater odds of response compared to risperidone or haloperidol-treated patients. However, olanzapine patients gained more weight than patients in other treatment groups. The incidence of motor dysfunction was significantly (P0.001) greater in haloperidol-treated patients, relative to the atypical treatment groups. Conclusion. The results of this observational study indicate that, in these patients with schizophrenia, long-term monotherapy with olanzapine may offer benefits over risperidone and haloperidol, but the potential for weight gain should be considered in the clinical management of these patients. |
| first_indexed | 2024-03-06T05:27:37Z |
| format | Article |
| id | um.eprints-11046 |
| institution | Universiti Malaya |
| last_indexed | 2024-03-06T05:27:37Z |
| publishDate | 2008 |
| record_format | dspace |
| spelling | um.eprints-110462014-12-17T01:52:12Z http://eprints.um.edu.my/11046/ Long-term, naturalistic treatment with olanzapine, risperidone, quetiapine, or haloperidol monotherapy: 24-month results from the intercontinental schizophrenia outpatient health outcomes (IC-SOHO) study Lee, P. Kim, C.E. Kim, C.Y. Lin, W. W. Habil, H. Dyachkova, Y. McBride, M. Dossenbach, M. R Medicine Objective. To compare the effectiveness of olanzapine, risperidone, quetiapine, or haloperidol monotherapy in patients with schizophrenia who were treated in routine clinical practice settings for a period of 2 years. The incidence and persistence of adverse events encountered during long-term therapy are also reported. Method. Outpatients with schizophrenia who entered this 3-year, prospective, observational study were classified according to their initially prescribed antipsychotic monotherapy: olanzapine (n=3222), risperidone (n=1116), quetiapine (n=189), or haloperidol (n=256). Patients were included in the analysis for as long as this treatment was maintained. Results. Over 2 years, olanzapine recipients had significantly (P0.001) greater reduction in overall CGI-S score (and the negative, depressive, and cognitive symptoms domains), lower incidence of sexual and motor dysfunction, and greater odds of response compared to risperidone or haloperidol-treated patients. However, olanzapine patients gained more weight than patients in other treatment groups. The incidence of motor dysfunction was significantly (P0.001) greater in haloperidol-treated patients, relative to the atypical treatment groups. Conclusion. The results of this observational study indicate that, in these patients with schizophrenia, long-term monotherapy with olanzapine may offer benefits over risperidone and haloperidol, but the potential for weight gain should be considered in the clinical management of these patients. 2008 Article PeerReviewed Lee, P. and Kim, C.E. and Kim, C.Y. and Lin, W. W. and Habil, H. and Dyachkova, Y. and McBride, M. and Dossenbach, M. (2008) Long-term, naturalistic treatment with olanzapine, risperidone, quetiapine, or haloperidol monotherapy: 24-month results from the intercontinental schizophrenia outpatient health outcomes (IC-SOHO) study. International Journal of Psychiatry in Clinical Practice, 12 (3). pp. 215-227. ISSN 1365-1501, DOI https://doi.org/10.1080/13651500801976634 <https://doi.org/10.1080/13651500801976634>. http://informahealthcare.com/doi/abs/10.1080/13651500801976634 10.1080/13651500801976634 |
| spellingShingle | R Medicine Lee, P. Kim, C.E. Kim, C.Y. Lin, W. W. Habil, H. Dyachkova, Y. McBride, M. Dossenbach, M. Long-term, naturalistic treatment with olanzapine, risperidone, quetiapine, or haloperidol monotherapy: 24-month results from the intercontinental schizophrenia outpatient health outcomes (IC-SOHO) study |
| title | Long-term, naturalistic treatment with olanzapine, risperidone, quetiapine, or haloperidol monotherapy: 24-month results from the intercontinental schizophrenia outpatient health outcomes (IC-SOHO) study |
| title_full | Long-term, naturalistic treatment with olanzapine, risperidone, quetiapine, or haloperidol monotherapy: 24-month results from the intercontinental schizophrenia outpatient health outcomes (IC-SOHO) study |
| title_fullStr | Long-term, naturalistic treatment with olanzapine, risperidone, quetiapine, or haloperidol monotherapy: 24-month results from the intercontinental schizophrenia outpatient health outcomes (IC-SOHO) study |
| title_full_unstemmed | Long-term, naturalistic treatment with olanzapine, risperidone, quetiapine, or haloperidol monotherapy: 24-month results from the intercontinental schizophrenia outpatient health outcomes (IC-SOHO) study |
| title_short | Long-term, naturalistic treatment with olanzapine, risperidone, quetiapine, or haloperidol monotherapy: 24-month results from the intercontinental schizophrenia outpatient health outcomes (IC-SOHO) study |
| title_sort | long term naturalistic treatment with olanzapine risperidone quetiapine or haloperidol monotherapy 24 month results from the intercontinental schizophrenia outpatient health outcomes ic soho study |
| topic | R Medicine |
| work_keys_str_mv | AT leep longtermnaturalistictreatmentwitholanzapinerisperidonequetiapineorhaloperidolmonotherapy24monthresultsfromtheintercontinentalschizophreniaoutpatienthealthoutcomesicsohostudy AT kimce longtermnaturalistictreatmentwitholanzapinerisperidonequetiapineorhaloperidolmonotherapy24monthresultsfromtheintercontinentalschizophreniaoutpatienthealthoutcomesicsohostudy AT kimcy longtermnaturalistictreatmentwitholanzapinerisperidonequetiapineorhaloperidolmonotherapy24monthresultsfromtheintercontinentalschizophreniaoutpatienthealthoutcomesicsohostudy AT linww longtermnaturalistictreatmentwitholanzapinerisperidonequetiapineorhaloperidolmonotherapy24monthresultsfromtheintercontinentalschizophreniaoutpatienthealthoutcomesicsohostudy AT habilh longtermnaturalistictreatmentwitholanzapinerisperidonequetiapineorhaloperidolmonotherapy24monthresultsfromtheintercontinentalschizophreniaoutpatienthealthoutcomesicsohostudy AT dyachkovay longtermnaturalistictreatmentwitholanzapinerisperidonequetiapineorhaloperidolmonotherapy24monthresultsfromtheintercontinentalschizophreniaoutpatienthealthoutcomesicsohostudy AT mcbridem longtermnaturalistictreatmentwitholanzapinerisperidonequetiapineorhaloperidolmonotherapy24monthresultsfromtheintercontinentalschizophreniaoutpatienthealthoutcomesicsohostudy AT dossenbachm longtermnaturalistictreatmentwitholanzapinerisperidonequetiapineorhaloperidolmonotherapy24monthresultsfromtheintercontinentalschizophreniaoutpatienthealthoutcomesicsohostudy |